Cosmo Pharmaceuticals N.V. (ETR:C43)

Market Cap	1.16B
Revenue (ttm)	185.36M
Net Income (ttm)	69.57M
Shares Out	n/a
EPS (ttm)	4.32
PE Ratio	16.73
Forward PE	n/a
Dividend	2.00 (2.92%)
Ex-Dividend Date	n/a

Volume	50
Average Volume	38
Open	67.50
Previous Close	68.50
Day's Range	67.50 - 68.50
52-Week Range	61.50 - 86.50
Beta	n/a
RSI	55.39
Earnings Date	Mar 6, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 325
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: C43